Hyperglycemia associated with protease inhibitors in HIV-1-infected patients

Clinical Microbiology and Infection

Volumn 6, Issue 7, 2000, Pages 389-392

  Gomez Vera J ^a   De Alarcon A ^a   Jimenez Mejias M E ^a   Acosta, D ^a   Prados, D ^a   Viciana, P ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; COTRIMOXAZOLE; DIDANOSINE; INDINAVIR; INSULIN; LAMIVUDINE; MEGESTROL; NELFINAVIR; PENTAMIDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TROGLITAZONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INSULIN RESISTANCE; KETOACIDOSIS; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; C-PEPTIDE; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HIV INFECTIONS; HIV-1; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; PROTEASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034236210     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2000.00083.x     Document Type: Article

References (38)

1. FDA Public Health Advisory: Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV)
2. FDA Public Health Advisory in protease inhibitors for HIV treatment
3. Hyperglycemia associated with protease inhibitors in HIV-infected patients
4. Diabetes and hyperglycemia in patients receiving protease inhibitors
5. Protease inhibitor-associated hyperglycaemia
6. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
7. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
8. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors
9. Diabetes and use of protease inhibitors
10. Hipertrigliceridemia y diabetes mellitus asociadas al uso de inhibidores de la proteasa en los pacientes con infección por el VIH
11. Severe diabetes associated with protease inhibitor therapy
12. New-onset diabetes mellitus associated with use of protease inhibitor
13. Exacerbated hyperglycemia associated with nelfinavir
14. Effects of protease inhibitor use on hyperglycemia and hyperlipidemia: A five year analysis
15. Prevalence and risk factors for hyperglycemia, dyslipemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy
16. High prevalence of impaired glucose tolerance prior to initiating protease inhibitor therapy
17. Diabetes mellitus following intravenous pentamidine administration in a patient with HIV infection
18. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia
19. Didanosine-induced disorders of glucose intolerance
20. Stimulation of 'Prohormone Thiol Protease' (PTP) and [Met] encephalin by forskolin
21. Impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function
22. Severe diabetes associated with protease inhibitor therapy
23. Immunological identification and localization of yeast aspartic protease 3-like prohormone processing enzymes in mammalian brain and pituitary
24. Indinavir associated lipodystrophy
25. Hypertrophy of the breast in a patient treated with indinavir
26. Visceral abdominal-fat accumulation associated with the use of indinavir
27. 'Buffalo hump' in men with HIV-1 infection
28. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
29. The fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
30. Effects of nonesterified fatty acid availability on tissue specific glucose utilisation in rats in vivo
31. Metabolic abnormalities and use of HIV-1 protease inhibitors
32. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitors (PI)
33. Effects of the PPAR-activator-troglitazone on protease inhibitor associated peripheral insulin resistance
34. Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping Pis or switching to nelfinavir
35. Reversal of hyperlipidaemia and lipodystrophy in patients switching therapy to nelfinavir
36. Protease inhibitor-associated hyperglycemia. Results of switching from indinavir to nelfinavir.nelfinavir
37. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
38. Management of indinavir-associated metabolic changes by substitution with efavirenz in virologically controlled HIV+ persons